XPOVIO® Gains Approval in Hong Kong for Expanded Cancer Treatments

The Hong Kong Department of Health has granted approval for XPOVIO® (selinexor) to be used for two additional indications in the treatment of multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). This announcement, made by Antengene Corporation Limited, signifies a significant advancement in the therapeutic options available for patients suffering from these malignancies.

The new approvals include the use of XPOVIO® as a monotherapy for patients with relapsed or refractory DLBCL and as part of a combination treatment alongside bortezomib and dexamethasone for adult patients with MM who have undergone at least one prior therapy. This brings the total number of approved indications for XPOVIO® in Hong Kong to three, following its earlier approval for use in combination with dexamethasone for relapsed or refractory MM.

Expanding Treatment Options for Patients

With the introduction of these new indications, XPOVIO® stands to benefit a broader range of patients. The approval marks a pivotal moment as XPOVIO® becomes the first approved selective XPO1 inhibitor in Hong Kong. Its unique mechanism of action provides a novel treatment pathway for patients who have limited options after exhausting other therapies.

This expansion is particularly crucial given the challenges associated with treating DLBCL, which can often be resistant to standard treatments. The approval allows healthcare providers in Hong Kong to offer more comprehensive care to patients who are not candidates for hematopoietic cell transplantation after multiple lines of systemic therapy.

Antengene has established a strong presence in the Asia Pacific region, with XPOVIO® already approved in ten countries and included in national insurance schemes in five markets, including China, Taiwan, Australia, Singapore, and South Korea. The company anticipates that XPOVIO® will receive further public insurance coverage across additional markets in the region.

About Antengene and Its Pipeline

Antengene Corporation Limited, listed on the Hong Kong Stock Exchange under the ticker 6996.HK, is dedicated to developing first-in-class and best-in-class therapeutics for various serious medical conditions. The company’s research and development pipeline extends from preclinical to commercial stages, focusing on autoimmune diseases, solid tumors, and hematological malignancies.

In addition to XPOVIO®, Antengene’s portfolio includes innovative therapies like ATG-022, an antibody-drug conjugate targeting CLDN18.2, and ATG-037, an oral CD73 inhibitor. The company has made substantial progress, having obtained 32 investigational new drug approvals in both the United States and Asia, further signaling its commitment to addressing significant unmet medical needs.

Antengene’s lead commercial asset, XPOVIO®, continues to pave the way for innovative cancer therapies. As the company explores new markets and expands its therapeutic applications, the recent approvals in Hong Kong represent a significant milestone in enhancing cancer care for patients in the region.